Pulmonary Fibrosis

Metabolic intermediates were identified as active participants in fibrosis progression and potential targets for next-generation therapies.

Atomic force microscopy successfully identified nanomechanical changes in fibrotic lung tissue.

A Mendelian randomization study suggests Actinomyces plays a role in idiopathic pulmonary fibrosis, mediated by circulating inflammatory proteins.

The approval is the first in more than a decade for an idiopathic pulmonary fibrosis treatment.

A wearable cough monitor generated clinically useful cough data, but patients only wore the device about half of the days of the study period.

A recent study outlines how artificial intelligence advancements are transforming research and therapeutic strategies for idiopathic pulmonary fibrosis.

Patients with progressive pulmonary fibrosis had longer survival with antifibrotic therapy, but only if they met a key criteria.

Patients with acute exacerbations of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis face steep odds and benefit from palliative care.

Findings reveal that alternative polyadenylation regulates SASP factors and may fuel age-related pulmonary fibrosis.

Polyethylene terephthalate microplastics are the most common microplastics encountered in daily life, and there are several reasons why they may play a role in lung diseases like idiopathic pulmonary fibrosis.

While observational studies have previously pointed to an association, being able to identify causation has been difficult due to overlapping risk factors and confounding variables.

Strategies that combine ferroptosis inhibition with established antifibrotics could ultimately move treatment from slowing progression to truly reversing fibrosis, new research suggests.

The findings are part of a new wave of research that uses artificial intelligence (AI) to hasten scientific discovery.

Telomere length can be used in the diagnosis of interstitial lung diseases like idiopathic pulmonary fibrosis, but it likely also has therapeutic implications, according to a new report.

Patients with idiopathic pulmonary fibrosis are at a higher risk of certain cardiovascular diseases.

From alveolar injury to extracellular matrix accumulation, the complex biology of pulmonary fibrosis is being unraveled alongside explorations of both Western and traditional Chinese therapies.

Factors such as age, smoking status, and body mass index can help clinicians predict a patient’s risk of 30-day mortality.

With limited treatment options and potential for admission to the intensive care unit, researchers of a new paper highlighted the importance of discussing goals and initiating palliative care early on.

Thirty-six immune cell phenotypes were flagged as having an association with idiopathic pulmonary fibrosis (IPF).

Of 14 metabolites identified, 2 appeared to have “robust” causal relationships with idiopathic pulmonary fibrosis.

The findings suggest a role for assessment of variant-carrying status to predict disease progression in idiopathic pulmonary fibrosis (IPF).

A deep learning generative model is capable of autonomously learning about idiopathic pulmonary fibrosis.

The genes are all associated with cellular senescence, which is believed to play an important role in the development of idiopathic pulmonary fibrosis (IPF).

At 12 weeks, patients treated with ENV-101 showed statistically significant increases in lung volume compared with those receiving placebo.

The potential therapy for idiopathic pulmonary fibrosis is notable because not only was the small molecule discovered by artificial intelligence, but the drug’s target itself was, too.